EVELO BIOSCIENCES
Evelo Biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. Monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. These new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer. Monoclonal mi... crobials have the potential to fundamentally change traditional models of drug discovery and development. By finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, Evelo can improve the speed, cost and success of drug discovery and development. Evelo’s platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials. Evelo Biosciences was conceived and created within VentureLabs®, Flagship Pioneering’s institutional innovation foundry, and launched by Flagship in 2015.
EVELO BIOSCIENCES
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2015-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.evelobio.com
Total Employee:
51+
Status:
Active
Contact:
+1 617 577 0300
Email Addresses:
[email protected]
Total Funding:
281.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Bezoar Laboratories
Bezoar Laboratories is devoted to improving the health of humans, animals, and environment with innovative microbial solutions.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
PuraCath Medical
PuraCath Medical is dedicated to improving the quality of life for the dialysis patient by reducing infections.
Cogent Biosciences
Cogent Biosciences is a biopharmaceutical company that develops therapies for solid cancer tumors.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-07-12 | Epiva | Epiva acquired by Evelo Biosciences | N/A |
Investors List
Dementia Discovery Fund
Dementia Discovery Fund investment in Venture Round - Evelo Biosciences
Mayo Clinic Ventures
Mayo Clinic Ventures investment in Series B - Evelo Biosciences
Flagship Pioneering
Flagship Pioneering investment in Series B - Evelo Biosciences
GV
GV investment in Series B - Evelo Biosciences
Celgene
Celgene investment in Series B - Evelo Biosciences
Alexandria Venture Investments
Alexandria Venture Investments investment in Series B - Evelo Biosciences
Flagship Pioneering
Flagship Pioneering investment in Series A - Evelo Biosciences
Key Employee Changes
Official Site Inspections
http://www.evelobio.com Semrush global rank: 2.04 M Semrush visits lastest month: 10.27 K
- Host name: 209.17.116.163
- IP address: 209.17.116.163
- Location: Jacksonville United States
- Latitude: 30.1426
- Longitude: -81.5727
- Metro Code: 561
- Timezone: America/New_York
- Postal: 32258
More informations about "Evelo Biosciences"
Evelo Biosciences - Crunchbase Company Profile
Contact Email [email protected] Phone Number +1 617 577 0300 Evelo Biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials.See details»
Evelo Biosciences, Inc. (EVLO) Company Profile & Overview - Stock …
Oct 25, 2024 Company profile for Evelo Biosciences, Inc. (EVLO) with a description, list of executives, contact details and other key facts.See details»
Evelo Biosciences - LinkedIn
Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™, with systemic ...See details»
Evelo Biosciences Company Profile - Office Locations ... - Craft
Oct 9, 2024 Evelo Biosciences is a biotechnology company that develops oral biologics for the treatment of inflammatory diseases and cancer. It offers orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut.See details»
Team Members Archive - Page 2 of 3 - Evelo Bio
Andrea has also served on the board of Global Arts Live, a Boston-based performing arts nonprofit organization, since 2019. Prior to joining Evelo, Andrea held multiple leadership roles at GlaxoSmithKline, including Vice President and Head of Tempero Discovery Unit. Andrea has …See details»
Working At Evelo Biosciences: Company Overview and Culture
Mar 14, 2024 evelobio.com. Organization Type. Public. CEO. Balkrishan Gill Ph.d (Simba) Social Media. Evelo Biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines - monoclonal microbials. Monoclonal …See details»
Andrea Itano, Ph.D. - Evelo
Andrea Itano, Ph.D., has served as Senior Vice President, Head of Research since 2017. Andrea has also served on the board of Global Arts Live, a Boston-based performing arts nonprofit organization, since 2019. Prior to joining Evelo, Andrea held multiple leadership roles at …See details»
Evelo Biosciences - VentureRadar
"Evelo Therapeutics is dedicated to transforming cancer therapy through a deep understanding of the cancer microbiome. Evelo is discovering and developing Oncobiotic? therapies, novel treatments designed to attack cancer by disrupting the microbial environment which supports …See details»
Evelo Biosciences Announces Top-Line Results From its Phase 2 …
Oct 17, 2023 - Primary endpoint was not achieved – - Company exploring strategic alternatives and partnering opportunities for EDP1815 and its SINTAX platform - CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE ...See details»
Flagship-founded Evelo finds dissolution is only viable option
Nov 22, 2023 Evelo Biosciences is dissolving. One month after starting a search for strategic alternatives, the Flagship Ventures-backed microbiome biotech has found its only option is to close its doors and ...See details»
Evelo Biosciences Provides Clinical and Business Updates - Yahoo …
CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting ...See details»
Evelo Biosciences, biotech firm launched by Flagship, shuts down
Nov 22, 2023 Evelo Biosciences, a startup hoping to use the trillions of microbes in and on the human body to fight disease, is shutting down after running out of cash and viable drug candidates.See details»
Evelo Biosciences, a microbiome company launched by Flagship, …
Nov 24, 2023 Evelo Biosciences, a startup hoping to use the trillions of microbes in and on the human body to fight disease, is shutting down after running low on cash and seeing multiple drug trial failures.See details»
Mark Bodmer, Ph.D. - Evelo - evelobio.com
Mark Bodmer, Ph.D. has served as Chief Scientific Officer and President of Research and Development since 2016. Prior to joining Evelo, Mark was Vice President of New Medicines Therapeutics at UCB S.A. Mark also served as Senior Vice President of Immunoinflammation …See details»
Evelo Biosciences Announces Appointment of Mark Plinio as Chief ...
Jun 1, 2021 For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn. Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the ...See details»
Evelo Biosciences (EVLO) Stock Price, News & Analysis - MarketBeat
5 days ago Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has …See details»
Flagship-backed microbiome biotech Evelo to shut down
Nov 22, 2023 Evelo studied its lead drug candidate, EDP1815, in Phase 2 trials for atopic dermatitis and psoriasis. In April, the company halted work on EDP1815 in atopic dermatitis and turned its focus to a second experimental drug, EDP2939, which was also in testing for psoriasis.See details»
Evelo Biosciences Announces $25.5 Million Private Placement
CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation ...See details»
Evelo Biosciences Announces Appointments of Luca Scavo as Chief ...
CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today ...See details»
Jeffrey R. Moore - Evelo - evelobio.com
Jeffrey R. Moore has served as a member of the Board of Directors since July 2023. Mr. Moore has served as Senior Vice President, Facilities & Venture Debt at Flagship Pioneering (“Flagship”) since November 2021 and focuses on leading real estate and venture debt for the company. …See details»